SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

ESK-001, out of the 3 molecules, has the fullest target inhibition of TYK2 as measured by IC50 and IC90. This gives ESK-001 the ability to potentially increase efficacy with comparable dosing.